Allan MacKenzie-Graham

Allan MacKenzie-Graham

Auto-generated profile, based on publicly available information

Allan MacKenzie-Graham

University of California, Los Angeles, Ahmanson-Lovelace Brain Mapping Center, 635 Charles E Young Dr S, Los Angeles, CA 90095, USA

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in The Lancet Neurology
Verified
Journal Article
Closed access
RVRhonda R Voskuhl
Rhonda R Voskuhl
HWHeJing Wang
HeJing Wang
TWT C Jackson Wu
T C Jackson Wu
NSNancy L Sicotte
Nancy L Sicotte
KNKunio Nakamura
Kunio Nakamura
RERobert Elashoff
Robert Elashoff

20 January 2004 in Journal of Anatomy
Verified
Journal Article
Open access
PDF file
AMAllan MacKenzie‐Graham
Allan MacKenzie‐Graham
ELErh‐Fang Lee
Erh‐Fang Lee
IDIvo D. Dinov
Ivo D. Dinov
MBMihail Bota
Mihail Bota
DSDavid W. Shattuck
David W. Shattuck
ATArthur W. Toga
Arthur W. Toga
Strains of mice, through breeding or the disruption of normal genetic pathways, are widely used to model human diseases. Atlases are an invaluable aid in understanding the impact of such manipulations by providing a standard for comparison. We have developed a digital atlas of the adult C57BL/6J mouse brain as a comprehensive framework for storing and accessing the myriad types of information about the mouse brain. Our implementation was constructed using several different imaging techniques: magnetic resonance microscopy, blockface imaging, classical histology and immunohistochemistry. Along with raw and annotated images, it contains database management systems and a set of tools for comparing information from different techniques. The framework allows facile correlation of results from different animals, investigators or laboratories by establishing a canonical representation of the mouse brain and providing the tools for the insertion of independent data into the same space as the atlas. This tool will aid in managing the increasingly complex and voluminous amounts of information about the mammalian brain. It provides a framework that encompasses genetic information in the context of anatomical imaging and holds tremendous promise for producing new insights into the relationship between genotype and phenotype. We describe a suite of tools that enables the independent entry of other types of data, facile retrieval of information and straightforward display of images. Thus, the atlas becomes a framework for managing complex genetic and epigenetic information about the mouse brain. The atlas and associated tools may be accessed at http://www.loni.ucla.edu/MAP.

1 May 1997 in Journal of Neuroimmunology
Verified
Journal Article
Closed access
JDJoel M Dopp
Joel M Dopp
AMAllan Mackenzie-Graham
Allan Mackenzie-Graham
GOGlen C Otero
Glen C Otero
JMJean E Merrill
Jean E Merrill

1 January 2009 in Frontiers in Neuroinformatics
Verified
Journal Article
Open access
IDIvo D. Dinov
Ivo D. Dinov
JHJohn D Van Horn
John D Van Horn
KLKamen M Lozev
Kamen M Lozev
RMRico Magsipoc
Rico Magsipoc
PPPetros Petrosyan
Petros Petrosyan
ATArthur W Toga
Arthur W Toga
The LONI Pipeline is a graphical environment for construction, validation and execution of advanced neuroimaging data analysis protocols (Rex et al., 2003 ). It enables automated data format conversion, allows Grid utilization, facilitates data provenance, and provides a significant library of computational tools. There are two main advantages of the LONI Pipeline over other graphical analysis workflow architectures. It is built as a distributed Grid computing environment and permits efficient tool integration, protocol validation and broad resource distribution. To integrate existing data and computational tools within the LONI Pipeline environment, no modification of the resources themselves is required. The LONI Pipeline provides several types of process submissions based on the underlying server hardware infrastructure. Only workflow instructions and references to data, executable scripts and binary instructions are stored within the LONI Pipeline environment. This makes it portable, computationally efficient, distributed and independent of the individual binary processes involved in pipeline data-analysis workflows. We have expanded the LONI Pipeline (V.4.2) to include server-to-server (peer-to-peer) communication and a 3-tier failover infrastructure (Grid hardware, Sun Grid Engine/Distributed Resource Management Application API middleware, and the Pipeline server). Additionally, the LONI Pipeline provides three layers of background-server executions for all users/sites/systems. These new LONI Pipeline features facilitate resource-interoperability, decentralized computing, construction and validation of efficient and robust neuroimaging data-analysis workflows. Using brain imaging data from the Alzheimer’s Disease Neuroimaging Initiative (Mueller et al., 2005 ), we demonstrate integration of disparate resources, graphical construction of complex neuroimaging analysis protocols and distributed parallel computing. The LONI Pipeline, its features, specifications, documentation and usage are available online (http://Pipeline.loni.ucla.edu ).

1 January 2014 in NeuroImage: Clinical
Verified
Journal Article
Open access
FKFlorian Kurth
Florian Kurth
ELEileen Luders
Eileen Luders
NSNancy L. Sicotte
Nancy L. Sicotte
CGChristian Gaser
Christian Gaser
BGBarbara S. Giesser
Barbara S. Giesser
AMAllan Mackenzie-Graham
Allan Mackenzie-Graham
Multiple sclerosis (MS) is an inflammatory and neurodegenerative disease of the central nervous system. While current medication reduces relapses and inflammatory activity, it has only a modest effect on long-term disability and gray matter atrophy. Here, we have characterized the potential neuroprotective effects of testosterone on cerebral gray matter in a pilot clinical trial. Ten men with relapsing-remitting MS were included in this open-label phase II trial. Subjects were observed without treatment for 6 months, followed by testosterone treatment for another 12 months. Focal gray matter loss as a marker for neurodegeneration was assessed using voxel-based morphometry. During the non-treatment phase, significant voxel-wise gray matter decreases were widespread (p≤ 0.05 corrected). However, during testosterone treatment, gray matter loss was no longer evident. In fact, a significant gray matter increase in the right frontal cortex was observed (p≤ 0.05 corrected). These observations support the potential of testosterone treatment to stall (and perhaps even reverse) neurodegeneration associated with MS. Furthermore, they warrant the investigation of testosterone's neuroprotective effects in larger, placebo controlled MS trials as well as in other neurodegenerative diseases. This is the first report of gray matter increase as the result of treatment in MS.

1 June 1996 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
RVRhonda R. Voskuhl
Rhonda R. Voskuhl
HPHilda Pitchekian‐Halabi
Hilda Pitchekian‐Halabi
AMAllan Mackenzie‐Graham
Allan Mackenzie‐Graham
HMHenry F. McFarland
Henry F. McFarland
CRCedric S. Raine
Cedric S. Raine